Innovative device to treat brain cancer shows promise in early studiesMay 30, 2007New early data showed that an investigational device that specifically targets rapidly growing cancer cells with intermediate frequency electrical fields -- called Tumor-Treating Fields (TTFields) -- more than doubled the median overall survival rates in patients with recurrent glioblastoma multiforme (GBM), the most common and aggressive type of malignant brain tumor. These survival rates observed in the data were compared to historical data. This research, which includes the results of cell culture, animal and early phase human trials, appears in the current issue of the Proceedings of the National Academy of Sciences (PNAS). The device, called the Novo-TTF, uses electrical fields to disrupt tumor growth by interfering with cell division of cancerous cells, causing them to stop proliferating and die off instead of dividing and growing. Healthy brain cells rarely divide and have different electrical properties than cancerous brain cells. This allows the device to target cancer cells without affecting the healthy cells. At the time of publication, researchers found that among the 10 patients with recurring GBM treated with the Novo-TTF, the median length of time to disease progression was 26.1 weeks; progression free survival at six months was 50 percent; and median overall survival was 62.2 weeks. This is more than double the rates reported in historical data - approximately 9.5 weeks, 15.3%, and 29.3 weeks, respectively. "The novel mechanism of action of the Novo-TTF relies on the physical properties of the cancer cells, their shape and size, rather than the chemical make-up. We believe that this distinction enables the device to stop local proliferation and metastasis of cancer, which would explain the efficacy observed in these early findings," said Dr. Elion Kirson lead author and Vice President of Research and Development, NovoCure. "Based on our preliminary research, we believe that there is a high probability that TTFields may prove to be an effective and safe approach to treating a large number of human cancers." Edelman Public Relations |
|||||||||||||||||||||
| Related Brain Cancer Current Events and Brain Cancer News Articles Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. Magnetic nanoparticles to simultaneously diagnose, monitor and treat Whether it's magnetic nanoparticles (mNPs) giving an army of 'therapeutically armed' white blood cells direction to invade a deadly tumour's territory, or the use of mNPs to target specific nerve channels and induce nerve-led behaviour (such as the life-dependant thumping of our hearts), mNPs have come a long way in the past decade. Angiochem crosses BBB, shows safety, efficacy in phase 1/2 brain cancer studies Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases. Toward a nanomedicine for brain cancer In an advance toward better treatments for the most serious form of brain cancer, scientists in Illinois are reporting development of the first nanoparticles that seek out and destroy brain cancer cells without damaging nearby healthy cells. UM scientists pinpoint critical molecule to celiac disease, possibly other autoimmune disorders It was nine years ago that University of Maryland School of Medicine researchers discovered that a mysterious human protein called zonulin played a critical role in celiac disease and other autoimmune disorders, such as multiple sclerosis and diabetes. Experts warn over health check brain scans A new study has voiced concern about the growing market for brain screening tests, which people can buy as part of a general health MOT. Avastin dramatically improves response, survival in deadly recurrrent glioblastomas The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a deadly form of brain cancer that had recurred. Computational Process Zeroes in on Top Genetic Cancer Suspects Johns Hopkins engineers have devised innovative computer software that can sift through hundreds of genetic mutations and highlight the DNA changes that are most likely to promote cancer. NIH study reveals new genetic culprit in deadly skin cancer Drawing on the power of DNA sequencing, National Institutes of Health researchers have identified a new group of genetic mutations involved in the deadliest form of skin cancer, melanoma. NIH researchers identify key factor that stimulates brain cancer cells to spread Researchers funded by the National Institutes of Health have found that the activity of a protein in brain cells helps stimulate the spread of an aggressive brain cancer called glioblastoma multiforme (GBM). More Brain Cancer Current Events and Brain Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||